产品名称 Miptenalimab (anti-LAG3) 别名 LAG3抗体 | LAG3单克隆抗体 | LAG3药靶抗体 | CD223药靶抗体 | CD223单克隆抗体 | CD223抗体 英文别名 CD223 antibody | CD223 antigen antibody | FDC protein antibody | LAG-3 antibody | Lag3 antibody | LAG3_HUMAN antibody | Lymphocyte activating ...
产品名称 Encelimab (anti-LAG3) 别名 安沙利单抗 | 恩塞利单抗(抗 LAG3) 英文别名 CD223 antibody | CD223 antigen antibody | FDC protein antibody | LAG-3 antibody | Lag3 antibody | LAG3_HUMAN antibody | Lymphocyte activating 3 antibody | Lymphocyte activation gene 3 antibody | Lymphocyte ...
Official Symbol:LAG3 Accession Number(s):NP_002277.4 Human GeneID(s):3902 Important Comments:This antibody is expected to recognize the extra-cellular domain. Immunogen Peptide with sequence EDVSQAQAGTYTCH, from the internal region of the protein sequence according to NP_002277.4. ...
Provided is an anti-LAG-3 antibody that can be frequently administered to a non-rat animal. The anti-LAG-3 antibody comprises: (a) an L chain comprising an L-chain variable region that includes CDR1 having a QSLLDSDGNTY (SEQ ID NO. 16) amino acid sequence, CDR2 having an SVS amino...
anti- LAG-3 antibody 英文名称: anti- LAG-3 antibody 总访问: 96 国产/进口: 国产 半年访问: 7 产地/品牌: FineTest 产品类别: 抗体 规格: 20μg, 50μg, 100μg 最后更新: 2025-2-13 货号: FNab04676 CAS 号: 参考报价: 询价 立即询价 电话咨询 ...
别名:Lymphocyte Activation Gene-3; FDC Protein; CD223 类型:Monoclonal Antibody 来源:Purified from concentrated hybridoma tissue culture supernatant. 应用:ELISA, FUNC (Blocking), ICC, IHC, IP, WB 克隆号:11E3 免疫原:Recombinant human LAG-3. ...
北京索莱宝科技有限公司生产的Anti-LAG3 Polyclonal Antibody,最新报价:1600.00元/ul,背景资料Lymphocyte-activationprotein3belongstoIgsuperfamilyandcontains4extracellular
抗体名: Anti-Human CD223/LAG3 Antibody (LAG-525)(流式抗体) 亚型: IgG4, kappa 浓度: 1 mg/ml % 是否单克隆: 是 靶点: CD223/LAG3 免疫原: Human 宿主: Human 用途: 仅用于科研 保质期: 1 year 应用范围: FCM 产地: France 标记物: Unconjugate 品牌: AntibodySystem 包装规...
The present invention provides an anti-LAG-3 antibody capable of repeated administration even to animals other than rat. An anti-LAG-3 antibody comprising (a) a light chain comprising a light chain variable region containing CDR1 having the amino acid sequence of QSLLDSDGNTY (SEQ ID NO: 16...
凌虹先生:维立志博的研发管线中有 7 个项目已经或即将进入临床,其中进展最快的项目代号为 LBL-007 (anti-LAG3 单抗),该项目正与百济神州合作推进全球临床试验。我个人认为,在 PD-1 之后,LAG-3 是最具成药可能性的靶点。之所以有此结论,不仅仅基于 BMS 的数据,维立志博在 ASCO、AACR 等会议上已披露的临床...